Streamline Drug Development With A Lab Informatics Platform

By Lisa Postava, product marketing manager, IDBS

Over 80% of new drugs fail due to poor pharmacokinetic (PK) profiles. To reduce the risk of failure in the drug discovery process, it's essential to assess a compound's ADME-Tox properties early on. This article outlines a tiered approach to ADME-Tox studies that can help improve efficiency, reduce costs, and accelerate the drug development timeline. This approach, which incorporates in silico, in vitro, and in vivo assessments, provides a smarter path for drug developers.

Explore how a digital transformation can help drive both scientific and business success, and learn how to optimize your ADME-Tox studies to make more informed decisions about your drug candidates.